Back to search

University of Washington

Predicting maternal-fetal cannabinoid exposure during pregnancy using physiologically-based pharmacokinetic modeling and simulation

Abstract

dc:description.abstract

Maternal marijuana (cannabis) use during pregnancy is associated with reduced fetal growth and subtle but persistent neurodevelopmental effects. It is not possible to establish the independent risk associated with maternal cannabis use via prospective clinical studies due to ethical considerations. In vitro and animal studies identified (-)-Δ9-tetrahydrocannabinol (THC), the psychotropic component of cannabis, and its active hydroxy metabolite, 11-OH-THC, as potential perpetrators of fetal developmental risk. The observed toxicity to THC and 11-OH-THC may not be translated from preclinical studies to humans without knowing the exposure of these cannabinoids during pregnancy. As such, maternal-fetal cannabinoid (hereafter cannabinoid refers to THC and 11-OH-THC) exposure needs to be determined. However, sampling maternal and fetal cannabinoid plasma concentrations during pregnancy is logistically difficult or unethical. Physiological-based pharmacokinetic (PBPK) modeling and simulation can be used to predict drug exposure in silico. PBPK modeling incorporates physiological data, such as tissue composition and blood flows, with drug specific pharmacokinetic (PK) parameters, such as metabolism and transport, to mechanistically predict in vivo PK of a drug. We hypothesize that we can predict maternal and fetal THC and 11-OH-THC exposure using maternal-fetal-PBPK (m-f-PBPK) modeling and simulation. To do so, we first quantified the pertinent mechanistic drug parameters in vitro, which included the identification of enzymes, their contribution, and kinetics relevant to maternal THC/11-OH-THC hepatic disposition. Next, we extrapolated the in vitro mechanistic information to in vivo and built a THC/11-OH-THC PBPK model in nonpregnant women using PBPK software Simcyp®, and verified using observed data. Lastly, we incorporated the gestational-age dependent physiological changes via the m-f-PBPK model to predict THC and 11-OH-THC exposure in the maternal-fetal pair. By bridging cannabinoid disposition data with m-f-PBPK modeling, this project translated in vitro PK mechanistic information into predictions of maternal and fetal pharmacologically relevant cannabinoid exposure following THC consumption. The predicted THC and 11-OH-THC concentrations during pregnancy can then be used in preclinical studies to establish the toxicity of THC exposure during pregnancy.

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Patilea-Vrana, Gabriela Ioana
Advisor dc:contributor.advisor
  • Unadkat, Jashvant D

Subjects

dc:subject × 7

Rights

dc:rights
Statement dc:rights
  • CC BY-NC-ND
Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1773/43729

Chain of custody

source
Harvested from
University of Washington
Base URL
digital.lib.washington.edu/server/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Patilea-Vrana, Gabriela Ioana. Predicting maternal-fetal cannabinoid exposure during pregnancy using physiologically-based pharmacokinetic modeling and simulation. 2019. http://hdl.handle.net/1773/43729